Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

Yao, J. C., Hassan, M. M., Phan, A. T., Dagohoy, C. G., Leary, C. C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510 · see citing works

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

Yao, J. C., Shah, M. H., Ito, T., Lombard‐Bohas, C., Wolin, E. M., Cutsem, E. V., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,879 · see citing works

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Raymond, É., Dahan, L., Raoul, J., Bang, Y., Borbath, I., Lombard‐Bohas, C., Valle, J. W., Metrakos, P. P., Smith, D. M., Vinik, A. I., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567 · see citing works

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Rinke, A., Müller, H., Schade‐Brittinger, C., Klose, K., Barth, P. J., Wied, M., Mayer, C., Aminossadati, B., Pape, U., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,507 · see citing works

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

Caplin, M. E., Pavel, M. E., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L. R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1316158 · Cited by 1,937 · see citing works

Treatment With the Radiolabeled Somatostatin Analog [ 177 Lu-DOTA 0 ,Tyr 3 ]Octreotate: Toxicity, Efficacy, and Survival

Kwekkeboom, D. J., de Herder, W. W., Kam, B. L. R., van Eijck, C. H. J., van Essen, M., Kooij, P. P. M., Feelders, R. A., van Aken, M. O., & Krenning, E. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2553 · Cited by 1,454 · see citing works

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Pavel, M. E., Hainsworth, J. D., Baudin, É., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,054 · see citing works

Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study

Sørbye, H., Welin, S., Langer, S. W., Vestermark, L. W., Jessen, N. H., Osterlund, P. J., Dueland, S., Hofsli, E., Guren, M. G., Öhrling, K., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds276 · Cited by 1,031 · see citing works

Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival

Halfdanarson, T. R., Rabe, K. G., Rubin, J., & Petersen, G. M. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn351 · Cited by 895 · see citing works

The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors

Lawrence, B. J., Gustafsson, B. I., Chan, A. K. C., Svejda, B., Kidd, M. S., & Modlin, I. M. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.12.005 · Cited by 860 · see citing works

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

Strosberg, J., Fine, R. L., Choi, J., Nasir, A., Coppola, D., Chen, D., Helm, J. F., & Kvols, L. K. (2010) · Cancer · doi:10.1002/cncr.25425 · Cited by 763 · see citing works

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

Moertel, C. G., Hanley, J. A., & Johnson, L. A. (1980) · New England Journal of Medicine · doi:10.1056/nejm198011203032101 · Cited by 659 · see citing works

Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [ 90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers

Imhof, A., Brunner, P., Marincek, N., Briel, M., Schindler, C., Rasch, H. F., Mäcke, H. R., Rochlitz, C. F., Müller‐Brand, J., & Walter, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7873 · Cited by 638 · see citing works

Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group

Faiss, S., Pape, U., Böhmig, M., Dörffel, Y., Mansmann, U., Golder, W. A., Riecken, E. O., & Wiedenmann, B. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.142 · Cited by 499 · see citing works

18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors

Binderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjær, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1759 · Cited by 488 · see citing works

Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies

Jensen, R. T., Berna, M. J., Bingham, D. B., & Norton, J. A. (2008) · Cancer · doi:10.1002/cncr.23648 · Cited by 487 · see citing works

Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine Tumors

Ekeblad, S., Sundin, A., Janson, E. T., Welin, S., Granberg, D. O., Kindmark, H., Dunder, K., Kozlovacki, G., Örlefors, H., Sigurd, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2053 · Cited by 470 · see citing works

Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center

Janson, E. T., Holmberg, L., Stridsberg, M., Eriksson, B., Theodorsson, E., Wilander, E., & Öberg, K. (1997) · Annals of Oncology · doi:10.1023/a:1008215730767 · Cited by 452 · see citing works

Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors

Gupta, S. K., Johnson, M. M., Murthy, R., Ahrar, K., Wallace, M. J., Madoff, D. C., McRae, S. E., Hicks, M. E., Rao, S., Vauthey, J., et al. (2005) · Cancer · doi:10.1002/cncr.21389 · Cited by 429 · see citing works

Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas

Anderson, M. A., Carpenter, S. L., Thompson, N. W., Nostrant, T. T., Elta, G. H., & Scheiman, J. M. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.02480.x · Cited by 396 · see citing works

Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours

Modlin, I., Pavel, M., Kidd, M., & Gustafsson, B. (2009) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2009.04174.x · Cited by 392 · see citing works

O 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

Kulke, M. H., Hornick, J. L., Frauenhoffer, C., Hooshmand, S. M., Ryan, D. P., Enzinger, P. C., Meyerhardt, J. A., Clark, J. W., Stuart, K. E., Fuchs, C. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1476 · Cited by 380 · see citing works

The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas

Strosberg, J., Coppola, D., Klimstra, D. S., Phan, A. T., Kulke, M. H., Wiseman, G. A., & Kvols, L. K. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181ebb56f · Cited by 357 · see citing works

Clinical effect of temozolomide‐based chemotherapy in poorly differentiated endocrine carcinoma after progression on first‐line chemotherapy

Welin, S., Sørbye, H., Sebjornsen, S., Knappskog, S., Busch, C., & Öberg, K. (2011) · Cancer · doi:10.1002/cncr.26124 · Cited by 288 · see citing works

Functional Imaging of Neuroendocrine Tumors: A Head-to-Head Comparison of Somatostatin Receptor Scintigraphy, 123I-MIBG Scintigraphy, and 18F-FDG PET

Binderup, T., Knigge, U., Loft, A., Mortensen, J., Pfeifer, A., Federspiel, B., Hansen, C. P., Højgaard, L., & Kjær, A. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069765 · Cited by 278 · see citing works

Long‐Term Results of Surgery for Small Intestinal Neuroendocrine Tumors at a Tertiary Referral Center

Norlén, O., Stalberg, P. L. H., Öberg, K., Eriksson, J., Hedberg, J., Hessman, O., Janson, E. T., Hellman, P., & Åkerström, G. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1296-z · Cited by 259 · see citing works

Malignancies of the Appendix: Beyond Case Series Reports

McGory, M. L., Maggard, M. A., Kang, H., O’Connell, J. B., & Ko, C. Y. (2005) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0196-4 · Cited by 259 · see citing works

Liver Transplantation for Neuroendocrine Tumors in Europe—Results and Trends in Patient Selection

Treut, Y. P. L., Grégoire, É., Klempnauer, J. L., Belghiti, J., Jouve, É., Lerut, J. P., Castaing, D., Soubrane, O., Boillot, O., Mantion, G., et al. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e31828ee17c · Cited by 257 · see citing works

Octreotide Versus Octreotide Plus Interferon-Alpha in Endocrine Gastroenteropancreatic Tumors: A Randomized Trial

Arnold, R., Rinke, A., Klose, K., Müller, H., Wied, M., Zamzow, K., Schmidt, C., Schade‐Brittinger, C., Barth, P. J., Moll, R., et al. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00481-7 · Cited by 254 · see citing works

Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry

Korse, C. M., Taal, B. G., van Velthuysen, M. F., & Visser, O. J. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.022 · Cited by 240 · see citing works

Glycemic Control in Patients with Insulinoma Treated with Everolimus

Kulke, M. H., Bergsland, E. K., & Yao, J. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0806740 · Cited by 236 · see citing works

Predictive Value of 18F-FDG PET and Somatostatin Receptor Scintigraphy in Patients with Metastatic Endocrine Tumors

Garin, É., Jeune, F. L., Devillers, A., Marc Cuggia, A., de Lajarte‐Thirouard, A., Bouriel, C., Boucher, É., & Raoul, J. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057505 · Cited by 231 · see citing works

Chromogranin A and Neuron-Specific Enolase as Prognostic Markers in Patients with Advanced pNET Treated with Everolimus

Yao, J. C., Pavel, M. E., Phan, A. T., Kulke, M. H., Hoosen, S., Peter, J. S., Cherfi, A., & Öberg, K. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0666 · Cited by 226 · see citing works

Randomized clinical trial of the effect of interferon α on survival in patients with disseminated midgut carcinoid tumours

Kölby, L., Persson, G., Franzén, S., & Åhrén, B. (2003) · British journal of surgery · doi:10.1002/bjs.4149 · Cited by 222 · see citing works

Hepatic Metastases From Neuroendocrine Tumors With a “Thin Slice” Pathological Examination

Elias, D. M., Lefèvre, J. H., Duvillard, P., Goèré, D., Dromain, C., Dumont, F., & Baudin, É. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181bdf8cf · Cited by 200 · see citing works

A comparison between three commercial kits for chromogranin A measurements

Stridsberg, M., Eriksson, B. K., Öberg, K., & Janson, E. (2003) · Journal of Endocrinology · doi:10.1677/joe.0.1770337 · Cited by 200 · see citing works

Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study

Kvols, L. K., Öberg, K. E., O’Dorisio, T. M., Mohideen, P., de Herder, W. W., Arnold, R., Hu, K., Zhang, Y., Hughes, G., Anthony, L. B., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-11-0367 · Cited by 199 · see citing works

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

Villard, L., Romer, A., Marincek, N., Brunner, P., Koller, M. T., Schindler, C., Ng, Q. K.-T., Mäcke, H. R., Müller‐Brand, J., Rochlitz, C. F., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.2151 · Cited by 189 · see citing works

Clinical PET of Neuroendocrine Tumors Using64Cu-DOTATATE: First-in-Humans Study

Pfeifer, A., Knigge, U., Mortensen, J., Oturai, P., Berthelsen, A. K., Loft, A., Binderup, T., Rasmussen, P., Elema, D. R., Klausen, T. L., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.101469 · Cited by 185 · see citing works

Comparative Biodistribution and Radiation Dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in Patients with Neuroendocrine Tumors

Sandström, M., Velikyan, I., Garske‐Román, U., Sørensen, J., Eriksson, B. K., Granberg, D. O., Lundqvist, H., Sundin, A., & Lubberink, M. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.120600 · Cited by 162 · see citing works

FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide–platinum combination in patients with neuroendocrine carcinomas grade 3

Hentic, O., Hammel, P. R., Couvelard, A., Rebours, V., Zappa, M., Palazzo, M., Maire, F., Goujon, G., Gillet, A., Lévy, P., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0002 · Cited by 162 · see citing works

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases

Brenner, B., Shah, M. A., Gönen, M., Klimstra, D. S., Shia, J., & Kelsen, D. P. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601758 · Cited by 141 · see citing works

In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours — impact of peptide mass

Velikyan, I., Sundin, A., Eriksson, B. K., Lundqvist, H., Sørensen, J. C. H., Bergström, M., & Långström, B. (2010) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2009.11.008 · Cited by 137 · see citing works

Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases

Capurso, G., Rinzivillo, M., Bettini, R., Boninsegna, L., Fave, G. D., & Falconi, M. (2012) · British journal of surgery · doi:10.1002/bjs.8842 · Cited by 136 · see citing works

Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531)

D, S. M. M., & Nitti, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt377 · Cited by 129 · see citing works

Selective Internal Radiotherapy with Yttrium-90 Microspheres for Hepatic Metastatic Neuroendocrine Tumors: A Prospective Single Center Study

Kalinowski, M., Dreßler, M., König, A. O., El-Sheik, M., Rinke, A., Höffken, H., Gress, T. M., Arnold, R., Klose, K., & Wagner, H. (2009) · Digestion · doi:10.1159/000209849 · Cited by 125 · see citing works

Salvage Therapy with 177Lu-Octreotate in Patients with Bronchial and Gastroenteropancreatic Neuroendocrine Tumors

van Essen, M., Krenning, E. P., Kam, B. L. R., de Herder, W. W., Feelders, R. A., & Kwekkeboom, D. J. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.068957 · Cited by 123 · see citing works

Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours

Sundin, A. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.004 · Cited by 117 · see citing works

Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

Kanakis, G., & Kaltsas, G. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.006 · Cited by 115 · see citing works

Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project

van der Zwan, J. M., Trama, A., Otter, R., Larrañaga, N., Tavilla, A., Marcos‐Gragera, R., Tos, A. P. D., Baudin, É., Poston, G. J., & Links, T. P. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.029 · Cited by 115 · see citing works

Elevated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors

Welin, S., Stridsberg, M., Cunningham, J. L., Granberg, D. O., Skogseid, B. M., Eriksson, B. K., & Janson, E. T. (2009) · Neuroendocrinology · doi:10.1159/000179900 · Cited by 114 · see citing works

Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors

Eriksson, J., Stalberg, P. L. H., Nilsson, A., Krause, J., Lundberg, C. E., Skogseid, B. M., Granberg, D. O., Eriksson, B. K., Åkerström, G., & Hellman, P. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9510-3 · Cited by 110 · see citing works

Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI

Schraml, C., Schwenzer, N. F., Sperling, O., Aschoff, P., Lichy, M., Müller, M., Brendle, C., Werner, M. K., Claussen, C. D., & Pfannenberg, C. (2013) · Cancer Imaging · doi:10.1102/1470-7330.2013.0007 · Cited by 109 · see citing works

Hepatic Arterial Embolization versus Chemoembolization in the Treatment of Liver Metastases from Well-Differentiated Midgut Endocrine Tumors: A Prospective Randomized Study

Maire, F., Lombard‐Bohas, C., O’Toole, D., Vullierme, M., Rebours, V., Couvelard, A., Pelletier, A.-L., Zappa, M., Pilleul, F., Hentic, O., et al. (2012) · Neuroendocrinology · doi:10.1159/000336941 · Cited by 108 · see citing works

Small-cell carcinoma of the esophagus and gastroesophageal junction: review of the Memorial Sloan-Kettering experience

Ku, G. Y., Minsky, B. D., Rusch, V. W., Bains, M. S., Kelsen, D. P., & Ilson, D. H. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm476 · Cited by 106 · see citing works

Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review

Capurso, G., Bettini, R., Rinzivillo, M., Boninsegna, L., Fave, G. D., & Falconi, M. (2011) · Neuroendocrinology · doi:10.1159/000324770 · Cited by 104 · see citing works

Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors

Cunningham, J. L., de Ståhl, T. D., Sjöblom, T., Westin, G., Dumanski, J. P., & Janson, E. T. (2010) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20834 · Cited by 101 · see citing works

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

Ezziddin, S., Opitz, M., Attassi, M., Biermann, K., Sabet, A., Guhlke, S., Brockmann, H., Willinek, W. A., Wardelmann, E., Biersack, H., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1610-2 · Cited by 96 · see citing works

EUS-FNA for Pancreatic Neuroendocrine Tumors: A Tertiary Cancer Center Experience

Atiq, M., Bhutani, M. S., Bektaş, M., Lee, J. E., Gong, Y., Tamm, E. P., Shah, C., Ross, W. A., Yao, J., Raju, G. S., et al. (2011) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1912-7 · Cited by 95 · see citing works

Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon α for advanced carcinoid tumors: FNCLCC–FFCD 9710

Dahan, L., Bonnetain, F., Rougier, P. R., Raoul, J., Gamelin, E., Etienne, P.-L., Cadiot, G., Mitry, E., Smith, D. M., Cvitkovic, F., et al. (2009) · Endocrine Related Cancer · doi:10.1677/erc-09-0104 · Cited by 87 · see citing works

Pancreatic neuroendocrine tumor: Added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection

Brenner, R., Metens, T., Bali, M. A., Demetter, P., & Matos, C. (2012) · European Journal of Radiology · doi:10.1016/j.ejrad.2012.01.032 · Cited by 86 · see citing works

Sporadic nonfunctioning pancreatic neuroendocrine tumors: Prognostic significance of incidental diagnosis

Birnbaum, D. J., Gaujoux, S., Cherif, R., Dokmak, S., Fuks, D., Couvelard, A., Vullierme, M., Ronot, M., Ruszniewski, P. B., Belghiti, J., et al. (2013) · Surgery · doi:10.1016/j.surg.2013.08.007 · Cited by 66 · see citing works

Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours

Lepage, C., Bouvier, A., & Faivre, J. (2013) · European Journal of Endocrinology · doi:10.1530/eje-12-0418 · Cited by 65 · see citing works

Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead

Sundin, A., & Rockall, A. (2012) · Neuroendocrinology · doi:10.1159/000342270 · Cited by 57 · see citing works

Prophylactic Cholecystectomy in Midgut Carcinoid Patients

Norlén, O., Hessman, O., Stålberg, P., Åkerström, G., & Hellman, P. (2010) · World Journal of Surgery · doi:10.1007/s00268-010-0428-1 · Cited by 55 · see citing works

Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker

Tohmola, N., Itkonen, O., Sane, T., Markkanen, H. M., Joenväärä, S., Renkonen, R., & Hämäläinen, E. K. (2013) · Clinica Chimica Acta · doi:10.1016/j.cca.2013.10.025 · Cited by 54 · see citing works

Surgery for GEP-NETs

Knigge, U., & Hansen, C. P. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2012.12.005 · Cited by 53 · see citing works

Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors

Jensen, K. H., Hilsted, L., Jensen, C., Mynster, T., Rehfeld, J. F., & Knigge, U. (2012) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2012.733953 · Cited by 48 · see citing works

Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours

Massironi, S., Conte, D., Sciola, V., Pirola, L., Paggi, S., Fraquelli, M., Ciafardini, C., Spampatti, M. P., & PERACCHI, M. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.009 · Cited by 37 · see citing works

Biotherapies for GEP-NETs

Öberg, K. (2012) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2013.01.001 · Cited by 36 · see citing works

Evaluation of Chromogranin A Expression in Patients with Non-Neuroendocrine Tumours

Tropea, F. G., Baldari, S., Restifo, G., Fiorillo, M. T., Surace, P., & Herberg, A. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626120-00005 · Cited by 20 · see citing works

Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors

Gedde-Dahl, M., Thiis‐Evensen, E., Tjølsen, A. M., Mordal, K. S., Vatn, M., & Bergestuen, D. S. (2012) · Endocrine Connections · doi:10.1530/ec-12-0077 · Cited by 18 · see citing works

Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors

Baekdal, J., Krogh, J., Klose, M., Holmager, P., Langer, S. W., Oturai, P., Kjaer, A., Federspiel, B., Hilsted, L., Rehfeld, J. F., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10110881 · Cited by 17 · see citing works

True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours

Rehfeld, J. F., Broedbaek, K., Goetze, J. P., Knigge, U., & Hilsted, L. M. (2020) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2020.1759141 · Cited by 13 · see citing works

Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Janson, E. T., Knigge, U., Dam, G. A., Federspiel, B., Grønbæk, H., Stalberg, P. L. H., Langer, S. W., Kjær, A., Arola, J. T., Schalin‐Jäntti, C., et al. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1921262 · Cited by 167 · see citing works

Nordic Guidelines 2010 for diagnosis and treatment of gastroenteropancreatic neuroendocrine tumours

Janson, E. T., Sørbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Mathisen, Ø., Mortensen, J., Sundin, A., Thiis‐Evensen, E., et al. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.492791 · Cited by 75 · see citing works

SEOM-GETNE clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2022)

Capdevila, J., Gordoa, T. A., Carmona‐Bayonas, A., Carretero, A. C., García‐Carbonero, R., Pulido, E. G., Fonseca, P. J., Lamarca, Á., Huerta, Á. S., & Gallego-Plazas, J. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03205-6 · Cited by 15 · see citing works

JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

Ito, T., Masui, T., Komoto, I., Doi, R., OSAMURA, R. Y., Sakurai, A., Ikeda, M., Takano, K., Igarashi, H., Shimatsu, A., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01827-7 · Cited by 161 · see citing works

Current state in the daily practice of neuroendocrine neoplasms of gi and pancreatobiliary tracts

Adsay, V. N. (2018) · Pathology · doi:10.1016/j.pathol.2017.12.030